BMRA
Biomerica, Inc. [BMRA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BMRA Stock Summary
Top 10 Correlated ETFs
BMRA
Top 10 Correlated Stocks
BMRA
In the News
BMRA Financial details
Company Rating
Neutral
Market Cap
13.93M
Income
-6.35M
Revenue
5.41M
Book val./share
0.46
Cash/share
0.32
Dividend
-
Dividend %
-
Employees
62
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-2.91
Forward P/E
-
PEG
-6.2
P/S
3.33
P/B
1.67
P/C
2.35
P/FCF
-3.17
Quick Ratio
5.39
Current Ratio
6.63
Debt / Equity
0.11
LT Debt / Equity
0.07
-
-
EPS (TTM)
-0.38
EPS next Y
-
EPS next Q
-
EPS this Y
38.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.97%
Revenue last 5Y
0.53%
Revenue Q/Q
-35.1%
EPS Q/Q
22.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
14.54%
Inst Trans
0.44%
ROA
-47%
ROE
-69%
ROC
-0.56%
Gross Margin
17%
Oper. Margin
-118%
Profit Margin
-115%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.7-2.13
52W High
-
52W Low
-
RSI
32
Rel Volume
0.82
Avg Volume
55.65K
Volume
45.47K
Perf Week
-7.31%
Perf Month
-34.14%
Perf Quarter
-20.13%
Perf Half Y
4.28%
-
-
-
-
Beta
-1.038
-
-
Volatility
0.03%, 0.12%
Prev Close
-0.03%
Price
0.7508
Change
-1.21%
BMRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-05-31
| Metric | History | 2019-05-31 | 2020-05-31 | 2021-05-31 | 2022-05-31 | 2023-05-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.56 | 0.66 | 0.6 | 1.49 | 0.38 | |
| Net income per share | -0.26 | -0.23 | -0.54 | -0.36 | -0.5 | |
| Operating cash flow per share | -0.24 | -0.42 | -0.44 | -0.04 | -0.39 | |
| Free cash flow per share | -0.26 | -0.43 | -0.47 | -0.05 | -0.39 | |
| Cash per share | 0.07 | 0.85 | 0.35 | 0.47 | 0.69 | |
| Book value per share | 0.43 | 1.4 | 0.77 | 0.66 | 0.83 | |
| Tangible book value per share | 0.42 | 1.38 | 0.75 | 0.64 | 0.82 | |
| Share holders equity per share | 0.43 | 1.4 | 0.77 | 0.66 | 0.83 | |
| Interest debt per share | 0 | 0.18 | 0.14 | 0.11 | 0.08 | |
| Market cap | 20.73M | 64.56M | 43.54M | 44.36M | 19.39M | |
| Enterprise value | 20.04M | 57.7M | 40.96M | 39.82M | 10.75M | |
| P/E ratio | -8.66 | -27.6 | -6.73 | -9.79 | -2.72 | |
| Price to sales ratio | 3.99 | 9.65 | 6.05 | 2.35 | 3.63 | |
| POCF ratio | -9.24 | -15.02 | -8.29 | -92.31 | -3.54 | |
| PFCF ratio | -8.58 | -14.62 | -7.85 | -68.15 | -3.49 | |
| P/B Ratio | 5.21 | 4.54 | 4.72 | 5.33 | 1.65 | |
| PTB ratio | 5.21 | 4.54 | 4.72 | 5.33 | 1.65 | |
| EV to sales | 3.85 | 8.62 | 5.69 | 2.11 | 2.01 | |
| Enterprise value over EBITDA | -9.09 | -29.85 | -6.74 | -10.18 | -1.56 | |
| EV to operating cash flow | -8.93 | -13.43 | -7.8 | -82.86 | -1.96 | |
| EV to free cash flow | -8.3 | -13.06 | -7.38 | -61.18 | -1.94 | |
| Earnings yield | -0.12 | -0.04 | -0.15 | -0.1 | -0.37 | |
| Free cash flow yield | -0.12 | -0.07 | -0.13 | -0.01 | -0.29 | |
| Debt to equity | 0 | 0.13 | 0.18 | 0.17 | 0.09 | |
| Debt to assets | 0 | 0.1 | 0.14 | 0.12 | 0.07 | |
| Net debt to EBITDA | 0.31 | 3.55 | 0.42 | 1.16 | 1.26 | |
| Current ratio | 3.56 | 10 | 7.1 | 4.69 | 6.58 | |
| Interest coverage | -51.34K | -266.98K | -17.77K | -170.2 | 0 | |
| Income quality | 0.94 | 1.84 | 0.81 | 0.11 | 0.77 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.32 | 0.29 | 0.33 | 0.1 | 0.3 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.08 | 0.03 | 0.06 | 0.35 | 0.01 | |
| Capex to revenue | -0.03 | -0.02 | -0.04 | -0.01 | -0.01 | |
| Capex to depreciation | -1.05 | -0.3 | -0.79 | -0.29 | -0.22 | |
| Stock based compensation to revenue | 0.03 | 0.03 | 0.05 | 0.07 | 0.22 | |
| Graham number | 1.59 | 2.69 | 3.07 | 2.3 | 3.07 | |
| ROIC | -0.61 | -0.14 | -0.52 | -0.41 | -0.52 | |
| Return on tangible assets | -0.47 | -0.14 | -0.56 | -0.4 | -0.5 | |
| Graham Net | 0.17 | 0.82 | 0.36 | 0.37 | 0.6 | |
| Working capital | 3.23M | 13.29M | 7.93M | 7.42M | 10.85M | |
| Tangible asset value | 3.87M | 14.04M | 8.93M | 8.15M | 11.56M | |
| Net current asset value | 3.23M | 11.72M | 6.64M | 6.38M | 10.07M | |
| Invested capital | 0 | 0.13 | 0.18 | 0.17 | 0.09 | |
| Average receivables | 1.13M | 1.61M | 1.61M | 1.11M | 747.91K | |
| Average payables | 827.6K | 993.15K | 709.17K | 583.81K | 540K | |
| Average inventory | 2.16M | 2.5M | 3.03M | 2.81M | 2.24M | |
| Days sales outstanding | 102.09 | 96.31 | 73.77 | 14.97 | 49.36 | |
| Days payables outstanding | 93.34 | 73.34 | 23.51 | 16.9 | 25.66 | |
| Days of inventory on hand | 200.87 | 211.89 | 174.6 | 55.48 | 153.37 | |
| Receivables turnover | 3.58 | 3.79 | 4.95 | 24.39 | 7.39 | |
| Payables turnover | 3.91 | 4.98 | 15.53 | 21.6 | 14.22 | |
| Inventory turnover | 1.82 | 1.72 | 2.09 | 6.58 | 2.38 | |
| ROE | -0.6 | -0.16 | -0.7 | -0.54 | -0.61 | |
| Capex per share | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2024-02-29 for Q3
| Metric | History | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 | 2024-02-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 0.07 | 0.1 | 0.09 | 0.06 | |
| Net income per share | -0.12 | -0.11 | -0.07 | -0.09 | -0.11 | |
| Operating cash flow per share | -0.13 | -0.06 | -0.1 | -0.05 | 0 | |
| Free cash flow per share | -0.13 | -0.06 | -0.1 | -0.05 | 0 | |
| Cash per share | 0.25 | 0.58 | 0.47 | 0.42 | 0.32 | |
| Book value per share | 0.44 | 0.7 | 0.64 | 0.56 | 0.46 | |
| Tangible book value per share | 0.43 | 0.69 | 0.63 | 0.55 | 0.45 | |
| Share holders equity per share | 0.44 | 0.7 | 0.64 | 0.56 | 0.46 | |
| Interest debt per share | 0.08 | 0.07 | 0.06 | 0.06 | 0.05 | |
| Market cap | 36.4M | 23.05M | 21.53M | 15.64M | 20.52M | |
| Enterprise value | 34.23M | 14.41M | 14.55M | 9.45M | 16.07M | |
| P/E ratio | -5.52 | -3.21 | -4.76 | -2.6 | -2.67 | |
| Price to sales ratio | 32.75 | 20.8 | 12.57 | 9.98 | 20.18 | |
| POCF ratio | -21.1 | -23.94 | -12.86 | -18.58 | 0 | |
| PFCF ratio | -21.03 | -23.59 | -12.4 | -18.32 | 0 | |
| P/B Ratio | 6.08 | 1.97 | 2 | 1.67 | 2.63 | |
| PTB ratio | 6.08 | 1.97 | 2 | 1.67 | 2.63 | |
| EV to sales | 30.8 | 13 | 8.5 | 6.03 | 15.8 | |
| Enterprise value over EBITDA | -21.87 | -8.22 | -12.77 | -6.23 | -8.03 | |
| EV to operating cash flow | -19.85 | -14.97 | -8.69 | -11.22 | 0 | |
| EV to free cash flow | -19.78 | -14.75 | -8.38 | -11.06 | 0 | |
| Earnings yield | -0.05 | -0.08 | -0.05 | -0.1 | -0.09 | |
| Free cash flow yield | -0.05 | -0.04 | -0.08 | -0.05 | 0 | |
| Debt to equity | 0.2 | 0.09 | 0.09 | 0.1 | 0.11 | |
| Debt to assets | 0.14 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Net debt to EBITDA | 1.38 | 4.93 | 6.12 | 4.09 | 2.23 | |
| Current ratio | 4.65 | 6.58 | 6.63 | 5.63 | 4.44 | |
| Interest coverage | 45.76 | -15.48 | 0 | 0 | 0 | |
| Income quality | 1.05 | 0.54 | 1.48 | 0.56 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.35 | 0.33 | 0.28 | 0.26 | 0.34 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0 | 0.01 | 0.04 | 0.01 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.04 | -0.01 | 0 | |
| Capex to depreciation | -0.07 | -0.17 | -0.68 | -0.13 | 0 | |
| Stock based compensation to revenue | 0.35 | 0.16 | 0.1 | 0.08 | 0 | |
| Graham number | 1.11 | 1.29 | 0.98 | 1.06 | 1.09 | |
| ROIC | -0.2 | -0.13 | -0.1 | -0.14 | -0.21 | |
| Return on tangible assets | -0.2 | -0.13 | -0.09 | -0.13 | -0.19 | |
| Graham Net | 0.2 | 0.51 | 0.45 | 0.38 | 0.28 | |
| Working capital | 5.09M | 10.85M | 9.83M | 8.44M | 6.86M | |
| Tangible asset value | 5.83M | 11.56M | 10.57M | 9.18M | 7.59M | |
| Net current asset value | 4.26M | 10.07M | 9.12M | 7.82M | 6.31M | |
| Invested capital | 0.2 | 0.09 | 0.09 | 0.1 | 0.11 | |
| Average receivables | 802.29K | 738.28K | 1.08M | 1.25M | 1.1M | |
| Average payables | 528.65K | 365.61K | 528.5K | 748K | 391.5K | |
| Average inventory | 2.06M | 2.06M | 1.97M | 1.86M | 1.99M | |
| Days sales outstanding | 61.1 | 58.64 | 75.13 | 61.28 | 100 | |
| Days payables outstanding | 35.16 | 28.68 | 49.32 | 56.74 | 0 | |
| Days of inventory on hand | 187.42 | 171.43 | 129.85 | 133.41 | 0 | |
| Receivables turnover | 1.47 | 1.53 | 1.2 | 1.47 | 0.9 | |
| Payables turnover | 2.56 | 3.14 | 1.82 | 1.59 | 0 | |
| Inventory turnover | 0.48 | 0.53 | 0.69 | 0.67 | 0 | |
| ROE | -0.28 | -0.15 | -0.11 | -0.16 | -0.25 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BMRA Frequently Asked Questions
What is Biomerica, Inc. stock symbol ?
Biomerica, Inc. is a US stock , located in Irvine of Ca and trading under the symbol BMRA
What is Biomerica, Inc. stock quote today ?
Biomerica, Inc. stock price is $0.7508 today.
Is Biomerica, Inc. stock public?
Yes, Biomerica, Inc. is a publicly traded company.
Company Profile
- Volume Average 55.65K
- Market Capitalization 13.93M
- Employee 62
- CEO Mr. Zackary S. Irani
- Headquarters Irvine,CA,US
- IPO Date 1984-09-07
-
Website
https://www.biomerica.com 
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
